Information Provided By: 
Fly News Breaks for July 31, 2019
LIVN
Jul 31, 2019 | 13:31 EDT
Piper Jaffray analyst Matt O'Brien said LivaNova's report of some stabilization in the Neuromod franchise was a key takeaway from the company's Q2 results. He maintains his view that the Neuromod franchise will rebound in the second half of the year and that TRD is receiving minimal value despite the fact that the first enrollment in the TRD trial is still on track for late this quarter, O'Brien tells investors. He keeps an Overweight rating on LivaNova shares.
News For LIVN From the Last 2 Days
There are no results for your query LIVN
